6920 Pointe Inverness Way, Suite 140
Fort Wayne, IN, 46804
2604073977
On December 18, 2024, the FDA approved Ryoncil (Remestemcel-L-rknd) as the first and only off-the-shelf allogeneic bone marrow-derived mesenchymal stromal cell therapy for children who are two months old to adolescents with steroid-refractory acute graft-versus-host disease (SR-aGVHD).
Metabolic health has been a hot topic for the last couple of years, and that trend looks to continue in 2026.
